Can a Once-Daily cream tame psoriasis in toddlers?

NCT ID NCT04746911

Completed Disease control Sponsor: Arcutis Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a once-daily application of ARQ-151 cream 0.3% is safe and well-tolerated in children aged 2 to 5 with plaque psoriasis. Over four weeks, researchers measure how much of the drug enters the bloodstream and watch for any side effects or skin reactions. The goal is to see if this cream could be a viable treatment option for young children with this skin condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARQ-151 cream 0.3% (topical roflumilast)
What this could lead to: If successful, this could lead to a new topical treatment option for young children with plaque psoriasis, potentially easing symptoms with fewer side effects than systemic medications.
What could go wrong: This is a small, early-phase study with only 10 participants, so results may not apply broadly. The cream may cause skin reactions or not work as well in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS PSORIASIS

Contacts and locations

Locations

Arcutis Clinical Site 602

Coral Gables, Florida, 33146, United States
Arcutis Clinical Site 603

Mountain Brook, Alabama, 35223, United States
Arcutis Clinical Site 604

Scottsdale, Arizona, 85255, United States
Arcutis Clinical Site 605

Houston, Texas, 77030, United States
Arcutis Clinical Site 606

Arlington, Texas, 76001, United States
Arcutis Clinical Site 607

Miami, Florida, 33155, United States
Arcutis Clinical Site 608

Los Angeles, California, 90057, United States
Arcutis Clinical Site 609

Fountain Valley, California, 92708, United States
Arcutis Clinical Site 610

Boca Raton, Florida, 33428, United States
Arcutis Clinical Site 611

Rancho Santa Margarita, California, 92688, United States
Arcutis Clinical Site 613

Delray Beach, Florida, 33484, United States
Arcutis Clinical Site 618

Los Angeles, California, 90017, United States
Arcutis Clinical Site 619

Frisco, Texas, 75034, United States
Arcutis Clinical Site 621

Toronto, Ontario, M5G 1X8, Canada
Arcutis Clinical Site 627

West Lafayette, Indiana, 47906, United States
Arcutis Clinical Site 630

Santo Domingo, Dominican Republic
Arcutis Clinical Study Site 619

Frisco, Texas, 75034, United States
Arcutis Clinical Study Site 628

Miami, Florida, 33125, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.